Since PD-1/PD-L1 represented only one of many inhibitory immune checkpoints, exploration of other potential new immune modulators that could be blocked to expand the success of cancer immunotherapy and promote the anticancer immune response is urgently needed. This evidence concerns the gene PDCD1 and cancer.